Gene therapy for deafness: researchers track long-term safety and hearing gains

NCT ID NCT06696456

ENROLLING_BY_INVITATION Disease control Sponsor: Akouos, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 people who previously received a gene therapy (AAVAnc80-hOTOF) for hearing loss caused by otoferlin gene mutations. Researchers will monitor safety over the long term, checking for late side effects, and measure hearing improvements using brain response tests. The goal is to ensure the treatment remains safe and effective over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OTOFERLIN GENE-MEDIATED HEARING LOSS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

auditory neuropathy autosomal recessive nonsyndromic hearing loss 9 Deafness Deafness, Autosomal Recessive 9 hearing loss disorder Hearing Loss, Bilateral Hearing Loss, Sensorineural

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19146, United States

  • Hospital Sant Joan de Déu

    Esplugues de Llobregat, Barcelona, 08950, Spain

  • National Taiwan University Hospital

    Taipei, Taiwan, (R.O.C), 100, Taiwan

  • University of Iowa

    Iowa City, Iowa, 52242, United States